Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus

Journal of Gene Medicine

Volumn 12, Issue 6, 2010, Pages 545-554

  Hamada, Katsuyuki ^a   Zhang, Ting ^b   Desaki, Junzo ^b   Nakashiro, Koh Ichi ^b   Itoh, Hiroshi ^c   Tani, Kenzaburo ^d   Koyama, Yoshiyuki ^e   Hamakawa, Hiroyuki ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d KYUSHU UNIVERSITY HOSPITAL   (Japan)

^e OTSUMA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cervical cancer; Oncolytic carrier cell; Promoter; Squamous cell carcinoma; Squamous cell carcinoma antigen 1

Indexed keywords

LUCIFERASE; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; SQUAMOUS CELL CARCINOMA ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN 1; SQUAMOUS CELL CARCINOMA ANTIGEN 2; UNCLASSIFIED DRUG; ISOPROTEIN; ONCOLYTIC VIRUS; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ADENOVIRIDAE; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL PROLIFERATION; GENE THERAPY; GENETICS; METABOLISM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; PROMOTER REGION; SURVIVAL RATE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RNA, MESSENGER; SERPINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954585191     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1467     Document Type: Article

References (19)

1. Takeshima N, Suminami Y, Takeda O, Abe H, Okuno N, Kato H. Expression of mRNA of SCC antigen in squamous cells. Tumor Biol 1992; 13: 338-342.
2. Kato H, Torigoe H. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621-1628. (Pubitemid 8221737)
3. Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol 1987; 157: 433-439.
4. Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994; 55: 169-173.
5. Duk JM, de Bruijn HXA, Groenier KH, et al. Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 1990; 39: 186-194.
6. Takeshima N, Hirai Y, Katase K, Yano K, Yamauchi K, Hasumi K. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol 1998; 68: 263-266.
7. Schneider SS, Schick C, Fish KE, et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 1995; 92: 3147-3151.
8. Hamada K, Shinomiya H, Asano Y, et al. Molecular cloning of human squamous cell carcinoma antigen 1 gene and characterization of its promoter. Biochim Biophys Acta 2001; 91522: 1-8.
9. Sakaguchi Y, Kishi F, Murakami A, Suminami Y, Kato H. Structural analysis of human SCC antigen 2 promoter. Biochim Biophys Acta 1999; 1444: 111-116.
10. Hamada K, Hanakawa Y, Hashimoto K, et al. Gene expression of human squamous cell carcinoma antigens 1 and 2 in human cell lines. Oncol Rep 2001; 8: 347-54. (Pubitemid 33758092)
11. Hsu KF, Wu CL, Huang SC, et al. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther 2008; 15: 526-534.
12. Hamada K, Kohno S, Iwamoto M, et al. Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 2003; 63: 2506-2512.
13. Latham JPF, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
14. Hamada K, Desaki J, Nakagawa K, Shirakawa T, Gotoh A, Tagawa M. Carrier cell-mediated infection of a replication-competent adenovirus for cancer gene therapy. Mol Ther 2007; 15: 1121-1128.
15. Suminami Y, Kishi F, Nawata S, et al. Promoter analyses of SCC antigen genes. Biochim Biophys Acta 2005; 1727: 208-212.
16. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2231-2232.
17. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689-1699.
18. Shimada H, Matsubara H, Shiratori T, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006; 97: 554-561.
19. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.